Skip to contentA
Anika Therapeutics, Inc.
A
ANIKAnika Therapeutics, Inc. Q4 2020 · 10-K
Revenue$32.69M$32.69M+9.8% vs Q4 2019 Net Income-$15.66M-$15.66MN/M vs Q4 2019 EPS Diluted-$1.10-$1.10N/M vs Q4 2019 Gross Profit$16,745,000−20.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Anika Therapeutics, Inc. · CIK 898437 · Engraved from SEC EDGAR
derived
Operating Cash Flowderived$2,587,000−80.1% Free Cash Flowderived$2,138,000−83.2% Margins · derivedGross margin51.2%−19.7 pt vs Q4 2019
Operating margin-54.9%−71.1 pt vs Q4 2019
Net margin-47.9%−61.5 pt vs Q4 2019
ended Dec 31, 2020 · filed Mar 5, 2021 · 64 d after period end